Back to Featured Content

10 October 2024

How Avance Clinical’s In-house ClinicReady Service Supports Early-Stage Biotech Companies to Secure Funding

How Avance Clinical’s In-house ClinicReady Service Supports Early-Stage Biotech Companies to Secure Funding

For early-stage biotech companies, securing funding is often a significant challenge due to the complex and costly nature of drug development. Avance Clinical, a leading contract research organization (CRO), offers tailored consultancy services to help biotech companies navigate the investment process to bring their innovations to market. By providing customized drug development pathways, detailed budgeting for development activities, and strategic advice to optimize trial designs, Avance Clinical helps biotech companies make a compelling case to investors.

Continue reading

Mapping Out Drug Development Pathways

Drug development is a complex and expensive process, with many early-stage biotechs lacking the resources or expertise to navigate regulatory requirements, preclinical requirements, clinical trial designs, and timelines.

Through their ClinicReady process, Avance Clinical works with biotech companies to develop a comprehensive drug development roadmap. This includes planning for key milestones such as toxicology studies, animal models, and proof of concept, ensuring the drug is ready for clinical trials. By developing these clear, data-driven pathways, Avance helps biotechs present a credible, well-organized plan to potential investors, which is crucial for raising capital​.

Get Into Clinic Faster with Avance Clinical – find out more now.

Providing Detailed Budgets for Development Pathways

As well as presenting a clear path forward, biotech companies need to present potential investors with a clear financial plan that outlines expected costs for each phase of development. These budgets serve as the blueprint for how the funds will be allocated, making it easier for investors to understand the financial needs and potential returns of the project.

Avance Clinical’s team of experts works closely with biotech clients, considering all aspects of drug development, such as regulatory submissions, non-clinical requirements, clinical trial design, site selection, patient recruitment, data management, and safety monitoring. By providing granular budget forecasts for these activities, Avance Clinical ensures that biotech companies can present a transparent and well-organized financial plan to investors, which enhances their credibility and increases the likelihood of securing funding​.

In addition to providing detailed budgets and proposed operational strategies and efficiencies, Avance Clinical will also provide consultancy on investor decks, to ensure these are investor ready. The Avance Clinical team understands the importance of this pitch, as well as what life sciences investors are looking for through each raise.

Fast-Tracking Clinical Trials

Avance Clinical understands that time is money and this is always a critical factor in early-stage drug development. Delays in clinical trials can not only increase costs but also deter potential investors. Avance Clinical’s deep knowledge of the Australian regulatory environment, where early-phase trials can proceed without an Investigational New Drug (IND) application via approval from a Human Research Ethics Committee, offers a significant time advantage over other regions. By quickly generating early clinical data, Avance Clinical helps biotech companies demonstrate proof of concept sooner, which is crucial for attracting investment during pivotal early stages.

Aligning Milestones with Investor Expectations

In addition to creating detailed budgets and fast-tracking trials, Avance Clinical helps biotech companies align their development milestones with investor expectations. Investors typically look for specific markers of progress, such as reaching Phase I or II clinical trials, securing regulatory approvals, or demonstrating proof of concept. Avance’s consultants work with biotechs to ensure that their drug development plan includes these key milestones and that they are achievable within a realistic timeline.

By aligning clinical milestones with funding stages, Avance Clinical helps biotechs create a clear and compelling narrative that attracts investor interest. For example, biotechs may seek seed funding to cover preclinical studies and early regulatory activities, followed by a larger investment round once Phase I trials demonstrate safety and initial efficacy. Avance Clinical’s consultancy services provide the strategic foresight needed to plan for these transitions and ensure a continuous flow of capital.

Leveraging Financial Incentives

One of the standout benefits of partnering with Avance Clinical is their ability to help biotech companies leverage Australia’s R&D tax incentive program, which offers rebates of up to 43.5% on R&D expenses​. For cash-strapped startups, this incentive can significantly reduce the financial burden of planning and running clinical trials, making their funding requests more attractive to investors.

Conclusion

For early-stage biotech companies, securing funding is a challenging but crucial step in the drug development process. Avance Clinical offers bespoke consultancy services that overcome this challenge by providing customized drug development pathways, detailed budgets, and strategic tailored advice. By fast-tracking clinical trials, aligning milestones with investor expectations, and leveraging financial incentives, Avance Clinical enables biotech companies to present a compelling case to investors, increasing their chances of securing the funding needed to bring their innovative therapies to market.

Connect with Avance Clinical’s expert team for a confidential discussion about your upcoming clinical trial or drug development program.

Discover how Avance Clinical’s expertise can accelerate your clinical development—read more success stories here.

 

Related Items

The Rise of Chinese Biotechs and the Global CRO Question

6 August 2026

The Rise of Chinese Biotechs and the Global CRO Question

What's fueling the surge of Chinese biotechs onto the world stage, and what decisions do they face on the path to their first global clinical trial?

Read more
How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets

27 May 2026

How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets

In 2025, Harvill’s experience overseeing CROs through global expansion across Asia Pacific (APAC), Europe, and South America led him to take the helm at Avance Clinical, Australia’s leading CRO.

Read more
CNS Trials Are Difficult — Do They Have To Be?

11 March 2026

CNS Trials Are Difficult — Do They Have To Be?

Central nervous system (CNS) indications, including mood disorders, neurodegenerative and neurodevelopmental diseases, and chronic pain, affect more than three billion people worldwide and represent the leading cause of illness and disability globally1.

Read more
Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program

11 February 2026

Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program

Australia's pragmatic regulatory environment, accelerated timelines, globally accepted data, Research and Development Tax Incentive, and other advantages, have emerged as a compelling strategy for Phase I trials.

Read more
International Clinical Trials Autumn Issue Is Live

20 November 2025

International Clinical Trials Autumn Issue Is Live

The latest International Clinical Trials (ICT) Autumn Issue is now live, featuring an exclusive interview with Jemma Lawson, Avance Clinical’s Executive Vice President, Global Operations.

Read more
Cut Timelines and Costs in Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination

15 October 2025

Cut Timelines and Costs in Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination

Globally, cancer diagnoses are projected to reach 35.3 million new cases per year with death rates rising to 18.5 million by 2050.²

Read more
Unlocking the Potential of FDA Expedited Approval and Voucher Programs: An Avance Clinical Partnership Approach

15 October 2025

Unlocking the Potential of FDA Expedited Approval and Voucher Programs: An Avance Clinical Partnership Approach

Our integrated approach combines deep regulatory expertise with world-class operational resources to guide Sponsors through every aspect of these complex programs, from initial eligibility assessment to managing post-approval commitments.

Read more
Accelerating Development Through Parallel Execution and Rigorous Quality Controls

23 September 2025

Accelerating Development Through Parallel Execution and Rigorous Quality Controls

In a recent video interview with Applied Clinical Trials, Ben Edwards, Chief Operating Officer, Avance Clinical, discussed common challenges in biotech, emphasizing the importance of addressing preclinical package gaps to avoid delays.

Read more
Advancing Rare Disease Clinical Trials: A High-Touch, Patient-Centered Approach for Biotechs

17 April 2025

Advancing Rare Disease Clinical Trials: A High-Touch, Patient-Centered Approach for Biotechs

Avance Clinical supports biotech companies by employing patient-centered trial designs, innovative statistical methodologies, personalized patient support, and expert regulatory guidance.

Read more
Avance Clinical North America: Proven Expertise With Global Solutions For US Biotechs

6 March 2025

Avance Clinical North America: Proven Expertise With Global Solutions For US Biotechs

The success of a biotech drug development program often depends on the relationship it forms with its Clinical Research Organization (CRO) partner.

Read more
Ensure Seamless Clinical Trial Transition Across Global Markets

17 January 2025

Ensure Seamless Clinical Trial Transition Across Global Markets

To enable access to life-saving therapeutics, drug sponsors continue to explore new strategies for executing their clinical trials as rapidly and efficiently as possible.

Read more
Delivering High-Quality Trials With Expert Consultation And Management In Cancer Research

5 January 2025

Delivering High-Quality Trials With Expert Consultation And Management In Cancer Research

The rapidly evolving landscape of oncology clinical trials, driven by innovative technologies and deeper insights into cancer biology, presents unique challenges and opportunities for U.S. biotech companies.

Read more